Stockreport

Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder

Minerva Neurosciences, Inc  (NERV) 
Last minerva neurosciences, inc earnings: 3/9 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.minervaneurosciences.com/investor-relations
PDF MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpointsMIN-117 was generally well-tolerated with a safety profile comparable to placeboCompany [Read more]